Immix Biopharma (IMMX) Long-Term Debt Issuances (2021)
Quarterly results put Long-Term Debt Issuances at $100000.0 for Q2 2021, changed N/A from a year ago — trailing twelve months through Dec 2021 was $200000.0 (changed N/A YoY), and the annual figure for FY2021 was $200000.0, changed.
Immix Biopharma has reported Long-Term Debt Issuances over the past 1 years, most recently at $100000.0 for Q2 2021.
- Long-Term Debt Issuances reached $100000.0 in Q2 2021 per IMMX's latest filing, roughly flat from $100000.0 in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $100000.0 in Q1 2021 and bottomed at $100000.0 in Q1 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 2.73 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | - |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | - |
| 10 | Immix Biopharma | 476.17 Mn | 476.17 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 100,000.00 |
| Jun 30, 2021 | 100,000.00 |
| Mar 31, 2021 | 100,000.00 |
| Mar 31, 2021 | 100,000.00 |